Rival drugs group AstraZeneca posts its own first-quarter numbers on Thursday. The successful launch of ulcer drug Nexium is expected to boost sales, as will the delay to the patent challenge to its key drug Prilosec. AstraZeneca is also expected to give an update on how the development of its next big launch, the anti-cholesterol drug Crestor, is progressing.